Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
5(71.4%)
Phase 2
2(28.6%)
7Total
N/A(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04673578Phase 2Unknown

Adjunctive Celecoxib in Childhood-onset OCD Study

Role: collaborator

NCT03420495Not ApplicableCompleted

Decision-making Impairments in OCD: An Integrated Behavioral Economics Model

Role: collaborator

NCT01981317Not ApplicableCompleted

Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder

Role: collaborator

NCT00363298Not ApplicableCompleted

Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD

Role: collaborator

NCT00405535Not ApplicableCompleted

Adjunctive Glycine for Obsessive Compulsive Disorder

Role: collaborator

NCT00257361Phase 2Withdrawn

D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder

Role: collaborator

NCT01404871Not ApplicableCompleted

Predicting Medication Response in Obsessive Compulsive Disorder

Role: collaborator

All 7 trials loaded